The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Chi Chiu Mok

Tuen Mun Hospital

Department of Medicine

New Territories

Tsing Chung Koon Road

Hong Kong

[email]@yahoo.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Tuen Mun Hospital, Department of Medicine, New Territories, Tsing Chung Koon Road, Hong Kong. 2004 - 2012
  • Department of Medicine, Tuen Mun Hospital, China. 2012
  • Tuen Mun Hospital, China. 2005 - 2011
  • Tuen Mun Hospital, Chinese University of Hong Kong, China. 2011
  • Department of Medicine, Tuen Mun Hospital and Centre for Assessment and Treatment of Rheumatic Diseases, Pok Oi Hospital, China. 2008 - 2010

References

  1. Abatacept for systemic lupus erythematosus: the outlook. Mok, C.C. Expert. Opin. Biol. Ther (2012) [Pubmed]
  2. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Mok, C.C., Birmingham, D.J., Ho, L.Y., Hebert, L.A., Song, H., Rovin, B.H. Lupus (2012) [Pubmed]
  3. Extended report: raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Mok, C.C., Ying, K.Y., To, C.H., Ho, L.Y., Yu, K.L., Lee, H.K., Ma, K.M. Ann. Rheum. Dis. (2011) [Pubmed]
  4. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Mok, C.C., Tam, L.S., Chan, T.H., Lee, G.K., Li, E.K. Clin. Rheumatol. (2011) [Pubmed]
  5. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Mok, C.C., Kwok, C.L., Ho, L.Y., Chan, P.T., Yip, S.F. Arthritis Rheum. (2011) [Pubmed]
  6. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Mok, C.C., Ko, G.T., Ho, L.Y., Yu, K.L., Chan, P.T., To, C.H. Arthritis. Care. Res. (Hoboken) (2011) [Pubmed]
  7. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Mok, C.C., Wong, C.K., To, C.H., Lai, J.P., Lam, C.S. Arthritis. Care. Res. (Hoboken) (2011) [Pubmed]
  8. Minimal mesangial lupus nephritis: a systematic review. Mok, C.C., Cheung, T.T., Lo, W.H. Scand. J. Rheumatol. (2010) [Pubmed]
  9. Biomarkers for lupus nephritis: a critical appraisal. Mok, C.C. J. Biomed. Biotechnol. (2010) [Pubmed]
  10. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Mok, C.C., Poon, W.L., Lai, J.P., Wong, C.K., Chiu, S.M., Wong, C.K., Lun, S.W., Ko, G.T., Lam, C.W., Lam, C.S. Scand. J. Rheumatol. (2010) [Pubmed]
  11. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Mok, C.C., Ho, L.Y., Leung, H.W., Wong, L.G. Transl. Res (2010) [Pubmed]
  12. Update on emerging drug therapies for systemic lupus erythematosus. Mok, C.C. Expert. Opin. Emerg. Drugs (2010) [Pubmed]
  13. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Mok, C.C. Nat. Rev. Nephrol (2009) [Pubmed]
  14. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Mok, C.C., Ho, L.Y., Cheung, M.Y., Yu, K.L., To, C.H. Scand. J. Rheumatol. (2009) [Pubmed]
  15. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. Mok, C.C., Ho, L.Y., To, C.H. Scand. J. Rheumatol. (2009) [Pubmed]
  16. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Mok, C.C., Ying, K.Y., Yim, C.W., Ng, W.L., Wong, W.S. Lupus (2009) [Pubmed]
  17. Risk and predictors of work disability in Chinese patients with systemic lupus erythematosus. Mok, C.C., Cheung, M.Y., Ho, L.Y., Yu, K.L., To, C.H. Lupus (2008) [Pubmed]
  18. Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Mok, C.C., Ying, S.K., To, C.H., Ma, K.M. Bone (2008) [Pubmed]
  19. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. Mok, C.C., To, C.H., Mak, A., Poon, W.L. J. Rheumatol. (2008) [Pubmed]
  20. Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. Mok, C.C., To, C.H., Ma, K.M. Lupus (2008) [Pubmed]
  21. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P., Ma, K.M. Osteoporos. Int (2008) [Pubmed]
  22. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. Mok, C.C., To, C.H., Ho, L.Y., Yu, K.L. J. Rheumatol. (2008) [Pubmed]
  23. Hormone replacement therapy in systemic lupus erythematosus. Mok, C.C. Nature Clinical Practice. Rheumatology (2008) [Pubmed]
  24. Who should treat lupus nephritis: rheumatologists or nephrologists?. Mok, C.C. Nature Clinical Practice. Nephrology (2008) [Pubmed]
  25. Rituximab for refractory polymyositis: an open-label prospective study. Mok, C.C., Ho, L.Y., To, C.H. J. Rheumatol. (2007) [Pubmed]
  26. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Mok, C.C. Scand. J. Rheumatol. (2007) [Pubmed]
  27. Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study. Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P., Ho, L.Y., Au, T.C. Medicine. (Baltimore) (2007) [Pubmed]
  28. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine. Mok, C.C., Ying, K.Y., Mak, A., To, C.H., Szeto, M.L. Rheumatology. (Oxford) (2006) [Pubmed]
  29. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Mok, C.C., Ying, K.Y., Ng, W.L., Lee, K.W., To, C.H., Lau, C.S., Wong, R.W., Au, T.C. Am. J. Med. (2006) [Pubmed]
  30. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Mok, C.C. Scand. J. Rheumatol. (2006) [Pubmed]
  31. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Mok, C.C., To, C.H., Mak, A. Medicine. (Baltimore) (2006) [Pubmed]
  32. Therapeutic options for resistant lupus nephritis. Mok, C.C. Semin. Arthritis Rheum. (2006) [Pubmed]
  33. Emerging drug therapies for systemic lupus erythematosus. Mok, C.C. Expert. Opin. Emerg. Drugs (2006) [Pubmed]
  34. Diffuse skeletal hyperostosis and pseudohypoparathyroidism. Mak, A., Mok, C.C. Rheumatology. (Oxford) (2005) [Pubmed]
  35. Prognostic factors in lupus nephritis. Mok, C.C. Lupus (2005) [Pubmed]
  36. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Mok, C.C., Mak, A., Ma, K.M. Lupus (2005) [Pubmed]
  37. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Mok, C.C., Mak, A., Chu, W.P., To, C.H., Wong, S.N. Medicine. (Baltimore) (2005) [Pubmed]
  38. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P., Au, T.C. Kidney Int. (2005) [Pubmed]
  39. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Mok, C.C., Tang, S.S., To, C.H., Petri, M. Arthritis Rheum. (2005) [Pubmed]
  40. Investigations and management of gastrointestinal and hepatic manifestations of systemic lupus erythematosus. Mok, C.C. Best. Pract. Res. Clin. Rheumatol (2005) [Pubmed]
  41. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Mok, C.C., To, C.H., Mak, A., Ma, K.M. Arthritis Rheum. (2005) [Pubmed]
  42. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Mok, C.C., Tang, S.S. Am. J. Med. (2004) [Pubmed]
 
WikiGenes - Universities